Quitbot Program for Smoking Cessation
Trial Summary
What is the purpose of this trial?
This phase III trial compares two remote digital smoking cessation programs to see how well they work for quitting smoking.
Research Team
Jonathan B Bricker
Principal Investigator
Fred Hutch/University of Washington Cancer Consortium
Eligibility Criteria
This trial is for smokers who have smoked at least one cigarette daily for the past year, want to quit within a month, and are willing to try a digital program. They must live in the US, read English, not use other cessation methods, be open to random assignment to either program, and have daily access to a smartphone with text messaging and Facebook Messenger.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Control Smoking Cessation Program (Behavioural Intervention)
- Experimental Smoking Cessation Program (Behavioural Intervention)
- QuitBot Smoking Cessation Program (Behavioural Intervention)
- Texting Smoking Cessation Program (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Fred Hutchinson Cancer Research Center
Lead Sponsor
Dr. Nancy Davidson
Fred Hutchinson Cancer Research Center
Chief Medical Officer since 2020
MD from Harvard Medical School
Dr. Thomas J. Lynch Jr.
Fred Hutchinson Cancer Research Center
Chief Executive Officer since 2020
MD from Yale University, BA from Yale College
Fred Hutchinson Cancer Center
Lead Sponsor
Dr. W. Thomas Purcell
Fred Hutchinson Cancer Center
Chief Medical Officer since 2022
MD from Emory University School of Medicine, MBA from University of Chicago
Dr. Thomas J. Lynch Jr.
Fred Hutchinson Cancer Center
Chief Executive Officer since 2020
MD from Yale School of Medicine
National Cancer Institute (NCI)
Collaborator
Dr. Douglas R. Lowy
National Cancer Institute (NCI)
Chief Executive Officer since 2023
MD from New York University School of Medicine
Dr. Monica Bertagnolli
National Cancer Institute (NCI)
Chief Medical Officer since 2022
MD from Harvard Medical School